FDA Declares End to Tirzepatide Shortage, Impacting Compounded Versions of Mounjaro and Zepbound
FDA ends tirzepatide shortage, impacting compounded versions of Mounjaro and Zepbound. Compounding pharmacies must phase out tirzepatide products, potentially affecting cost and access to these weight-loss and diabetes drugs.